Friday, December 17, 2010
There are several medical ventures on Tel Aviv Stock Exchange but I own none of them. Yet the potential payback is fenomenal. For example, yesterday the Committee for Medicinal Products for Human Use (CHMP), the European FDA, granted marketing authorisation for Esbriet for treatment of idiopathic pulmonary fibrosis (IPF). The patent is owned by ITMN. Many fortunate people's lives will be saved. Some fortunate investors will be rich investors today. Pic.: Steven Cohen, rich investor. If ITMN's treatment for Hepatitis C is approved, he will be a very rich investor.